Blade Earnings Reports

Blade's Q4 2024 revenue grew by 14.5% to $54.4 million, driven by strong performance in the Medical segment. Net loss improved by 71.1% to $9.8 million, and Adjusted EBITDA saw a substantial improvement, reaching near break-even at $(0.4) million. Flight profit increased by 39.7%, with a flight margin expansion to 23.2%.

Blade Air Mobility reported a 4.8% increase in revenue to $74.9 million, driven by growth in the Medical and Short Distance segments. The company achieved positive Passenger Segment Adjusted EBITDA on a trailing twelve-month basis, ahead of schedule. They also announced a strategic alliance with OrganOx to enhance organ transplant logistics.

Blade Air Mobility reported an 11.4% increase in total revenue to $67.9 million, marking its first Adjusted EBITDA positive Q2 as a public company. The Medical and Passenger segments demonstrated strong performance, contributing positive Segment Adjusted EBITDA. The company is reaffirming its guidance for full year 2024, expecting revenue of $240 million to $250 million and positive Adjusted EBITDA.

Blade Air Mobility reported a 13.8% increase in total revenue to $51.5 million, driven by a 34.6% increase in Medical revenue. The company's net loss improved by 58.5% to $(4.2) million, and Adjusted EBITDA improved by 54.1% to $(3.5) million.

Blade Air Mobility reported a 24.5% increase in revenue to $47.5 million for Q4 2023, driven by strong growth in the MediMobility Organ Transport business. The net loss increased to $(33.9) million, primarily due to an impairment charge. Adjusted EBITDA improved to $(5.2) million.